What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1178748

Cover Image

PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1178748

Self-Administered Autoimmune Injectables to 2028

PAGES: 160 Pages
DELIVERY TIME: 1-2 business days
PDF (Single User License)
USD 4850
PDF (Site License)
USD 6500
PDF (Enterprise License)
USD 9500

Add to Cart

“Self-Administered Autoimmune Injectables to 2028” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of next generation injection devices on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Converging Factors Driving Self-administered Autoimmune Care

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.

What You Will Learn:

  • What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?
  • What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?
  • What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2028?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?
  • What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?
Product Code: SAK955V

Table of Contents

  • Executive Summary
  • Self-administered Autoimmune Injectables
  • Executive Summary
  • Market Dynamics
  • Competitive Landscape
  • Drug Supply Chain Activity
  • Product Design and Enablement Factors
  • Ease of Use
  • Patient Adherence
  • Dosing Frequency
  • Human Engineering/Ergonomics
  • Pre- and Post-Marketing Device Evolution
  • Self-administered Enabling Devices
  • Device Selection - Stability and Material Issues
  • Prefilled Syringes
  • Autoinjectors
  • Physioject (Becton Dickinson)
  • Sensoready Pen
  • Enbrel SureClick (Amgen)
  • SmartJect (PA Consulting/Centocor)
  • Pegasys Proclick (Genentech/Roche)
  • Special Feature Autoinjectors
  • Pen Injectors
  • Dual Chamber Pens
  • Emerging Devices
  • Self-administered Therapeutic Autoimmune Drugs
  • Actemra (Tocilizumab)
  • Benlysta (GSK/Human Genome Sciences)
  • Betaseron
  • Cosentyx
  • Extavia
  • Ilumya
  • Kineret
  • Tumor Necrosis Factors
  • Amjevita
  • Benepali
  • Enbrel (Etanercept)
  • Halimatoz
  • Hefiya
  • Simponi (Golimumab)
  • Ankylosing Spondylitis
  • Crohn's Disease
  • Adult Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Psoriatic Arthritis
  • Ulcerative Colitis
  • Market Factors
  • Regulatory Factors
  • Clinical Trial Protocols & Endpoints
  • Alliances and Partnerships
  • Company Profiles
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!